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Background: Constraint-induced movement therapy (CIMT) is among the most developed training
approaches for motor restoration of the upper extremity (UE).
Methods: Very Early Constraint-Induced Movement during Stroke Rehabilitation (VECTORS) was
a single-blind phase II trial of CIMT during acute inpatient rehabilitation comparing traditional UE
therapy with dose-matched and high-intensity CIMT protocols. Participants were adaptively ran-
domized on rehabilitation admission, and received 2 weeks of study-related treatments. The pri-
mary endpoint was the total Action Research Arm Test (ARAT) score on the more affected side at
90 days after stroke onset. A mixed model analysis was performed.
Results: A total of 52 participants (mean age 63.9  14 years) were randomized 9.65  4.5 days
after onset. Mean NIHSS was 5.3  1.8; mean total ARAT score was 22.5  15.6; 77% had
ischemic stroke. Groups were equivalent at baseline on all randomization variables. As expected,
all groups improved with time on the total ARAT score. There was a significant time x group
interaction (F  3.1, p  0.01), such that the high intensity CIT group had significantly less im-
provement at day 90. No significant differences were found between the dose-matched CIMT
and control groups at day 90. MRI of a subsample showed no evidence of activity-dependent
lesion enlargement.
Conclusion: Constraint-induced movement therapy (CIMT) was equally as effective but not supe-
rior to an equal dose of traditional therapy during inpatient stroke rehabilitation. Higher intensity
CIMT resulted in less motor improvement at 90 days, indicating an inverse dose-response relation-
ship. Motor intervention trials should control for dose, and higher doses of motor training cannot be
assumed to be more beneficial, particularly early after stroke. Neurology® 2009;73:195–201
GLOSSARY
ADC  apparent diffusion coefficient; ADL  activities of daily living; ARAT  Action Research Arm Test; CIMT  constraint-
induced movement therapy; DWI  diffusion-weighted imaging; FIM  Functional Independence Measure; NIHSS  NIH
Stroke Scale; SIS  Stroke Impact Scale; TE  echo time; TI  inversion time; TR  repetition time; UE  upper extremity;
VECTORS  Very Early Constraint-Induced Movement during Stroke Rehabilitation.
Stroke is a leading cause of disability, primarily from motor impairments. Experimental restor-
ative treatments include structured therapeutic activity and pharmacologic augmentation.1 For
the upper extremity (UE), constraint-induced movement therapy (CIMT) is among the most
developed approaches. The basic principles of CIMT were first explored long ago2 but interest
has surged recently.3,4 A phase III randomized controlled trial of CIMT initiated in the 3- to
9-month period after stroke onset found it superior to usual and customary care,5 with persis-
tent treatment response.6
The use of CIMT during the inpatient rehabilitation phase, if proven superior to conven-
tional rehabilitation, has several rationales. Substantial rehabilitation resources are expended
during this phase of care; more effective retraining might improve outcome without increasing
cost. Inpatient rehabilitation is the earliest point where CIMT is practical; early application
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might preempt learned non-use,7 and exploit
any early window for best response to motor
training.8 Our pilot trial provided a basis9 for
further study.
METHODS Participants. Acute stroke admissions at
Barnes-Jewish Hospital in St. Louis, MO, were screened for
study eligibility (figure 1). Three additional subjects were re-
ferred by outside neurologists. Subjects were included if they had
1) unilateral ischemic or hemorrhagic stroke (with confirmatory
neuroimaging) within 28 days of admission to inpatient rehabil-
itation; 2) persistent hemiparesis, generally indicated by a score
of 1–3 on the motor arm item of the NIH Stroke Scale
(NIHSS)10; 3) proximal UE voluntary activity indicated by a
score of 3 on the upper arm item of the Motor Assessment
Scale,11 but wrist and finger movement was not required; 4) pre-
served cognitive function as indicated by a) a score 1 on the
consciousness and communication items of the NIHSS, b) the
ability to perform two-step commands, and c) a score of 8 on
the Short Blessed Memory Orientation and Concentration
Scale12; and 5) no UE injury or conditions that limited use prior
to the stroke. Exclusion criteria included 1) inability to give in-
formed consent; 2) clinically significant fluctuations in mental
status within 3 days of enrollment; 3) not independent prior to
the index stroke (determined by scores 95 on the Barthel In-
dex13 or 1 on the Modified Rankin Scale14; 3) hemispatial ne-
glect as determined by asymmetry 3 errors on the Star
Cancellation Test15; 4) sensory loss 2 on the sensory item of
the NIHSS; 5) not expected to survive 1 year due to other
illnesses.
Interventions. VECTORS was a three-arm, single-blind, ran-
domized controlled trial approved by the Washington University
Human Studies Committee. The primary endpoint was the 90-
day Action Research Arm Test (ARAT). Trained raters per-
formed all blinded evaluations. Using baseline data collected on
rehabilitation admission, we adaptively randomized22 the groups
balancing for age, total NIHSS score, pretest ARAT score on the
affected side, and days from stroke onset to randomization.
Study treatments preempted occupational therapy and oc-
curred 5 days per week for 2 consecutive weeks. Prespecified
treatment protocols were developed based on our prior study and
incorporated features of the EXCITE trial5 manual. Subjects
otherwise received routine inpatient interdisciplinary stroke re-
habilitation. Research clinicians trained in study procedures pro-
vided all study-related treatments; all were licensed occupational
therapists or supervised assistants. The study clinical team met
weekly to assure adherence to protocols. Individual sessions and
circuit-training techniques were used in all three study groups.
The same group of therapists delivered both the experimental
and control treatments. Prespecified protocols, developed for
both the control and CIMT treatments, were focused primarily
on basic activities of daily living (ADL) tasks required for dis-
charge to the community.
The control treatment mimicked traditional occupational
therapy, involving compensatory techniques for ADL, range of
motion, and strengthening. This treatment consists of 1 hour of
ADL retraining and 1 hour of UE bilateral training activities.
Adaptive equipment and positioning devices were used; a pre-
specified cueing strategy neither encouraged nor discouraged the
use of the hemiparetic UE. Massed practice, shaping, and con-
straint were prohibited.
The standard CIMT group received 2 hours of shaping ther-
apy per day and wore a padded constraint mitten for 6 hours per
day. The high-intensity CIMT group underwent 3 hours per day
of shaping and wore the mitten for 90% of waking hours. This
therapy consisted of performance of basic ADL together with
supervised massed practice of skilled functional activities. These
activities were graded per the study protocol by the treating oc-
cupational therapist to match the subject’s motor performance.
Increasing levels of demand were based on increases in strength
and coordination of the involved joints. As participants achieved
successful completion of self-care activities and 80% of the trials
for each specific motor activity, the complexity or difficulty of
these activities were increased to the next level. Subjects received
extensive verbal and written feedback about their performance,
including a review of the prior day’s achievements, the day’s
proposed goals, and reinforcement of new gains and mainte-
nance of prior gains in graphic and verbal form appropriate to
the activities selected for the treatment session.
MRI substudy. In rodent brain infarct models, immediate
immobilization of the unaffected forelimb causes lesion enlarge-
ment by an excitotoxic mechanism.30,31 We therefore carried out
an MRI safety substudy in nine subjects with ischemic stroke
(two in the control group, four in the standard CIMT group,
and three in the high-intensity CIMT group) to ascertain
whether very early CIMT as employed in this study resulted in
expansion of ischemic lesions. Since both acute ischemia and
direct excitotoxic damage result in restricted diffusion by MRI,
we determined if any new areas with abnormalities on diffusion-
weighted imaging (DWI) and apparent diffusion coefficient
(ADC) measurements developed during the course of CIMT.38
An initial set of MRI scans was obtained between 1 and 22 days
following stroke immediately prior to beginning the VECTORS
treatments and a second set of scans 7–9 days later. MRI was
performed with a 1.5-T Magnetom Sonata using an eight-
channel head array and Syngo software. Following scout and
auto alignment sequences, each subject had fluid-attenuated in-
version recovery (repetition time [TR]/echo time [TE]/inversion
time [TI]  9,390/96/2,500, flip angle  180, matrix  192 
256, 64 2-mm-thick slices, voxels  1  1  2 mm), T2*
(TR/TE  2,700/61, flip angle  90, acquisition matrix 
80  128, 60 2-mm-thick slices, voxels  2  2  2 mm), and
single-shot spin-echo echoplanar DWI (TR/TE  10,000/80,
flip angle  90, acquisition matrix  80  128, 72 2-mm-thick
Figure 1 Screening algorithm
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slices, voxels  2  2  2 mm, b  0 and b  800 mm2/s) for
DWI and ADC measurements. Images for each subject were
coregistered using Automated Image Registration software (AIR
3.08, Roger Woods, UCLA). Subtraction images of coregistered
DWI and ADC image pairs for each subject were visually exam-
ined for new areas of DWI or ADC change. In addition, any
voxels within the area of infarction for which DWI intensities
increased by at least 40% and ADC values decreased by at least
10% between the first and second scans were identified. These
are conservative cutoffs based on a study that found mean DWI
intensities were at least 90% greater and mean ADC intensities
were at least 17% lower than normal within the first 7 days
following cerebral infarction.23 Scans from four subjects with in-
tracerebral hemorrhages were excluded from the analysis because
of the large changes in DWI/ADC signals for clotted blood that
occur over time.
Objectives. Our objective was to examine whether CIMT was
superior to an equivalent amount of traditional Occupational
Therapy, and whether CIMT treatment effects would be dose
dependent.
Outcomes. NIH Stroke Scale. The NIH Stroke Scale
(NIHSS)10 assesses cognitive, sensory, and motor impairments as
an indicator of overall stroke severity.
Action Research Arm Test. The total ARAT16 score in the
more affected UE was the primary dependent measure. The
ARAT assesses UE functional limitations with four ordinal sub-
scales: grasp, grip, pinch, and gross movement. Item scores are
summed to create subtest and full-scale scores; the maximum
score of 57 indicates normal performance.
Functional Independence Measure. The Functional Inde-
pendence Measure (FIM) is an 18-item disability measure.17 All
evaluators in this study were certified by the Uniform Data Sys-
tem. During the inpatient stay, the FIM was scored based on
performance; after discharge, we used the Fone Fim18 format
developed for telephone administration of the standard FIM
items. We created a FIM Upper Extremity Score by summing
the 5 FIM items requiring significant hand and arm use.
The Stroke Impact Scale (hand function subscale). The
five-item hand function subscale of the Stroke Impact Scale19
(SIS) assesses hand strength, dexterity, and fine and gross motor
ability associated with the ability to complete functional tasks.
Higher scores indicate greater function and life satisfaction.
Pain ratings. The Wong-Baker Faces Scale was used to
assess pain in the affected shoulder at days 0, 14, and 9020 and
during treatment.
Depression. The Geriatric Depression–15 Scale21 was used
to assess depression at days 0, 14, and 90. Scores below 5 are
normal.
Statistical methods. SAS Version 9 for Windows was used. A
modified intent to treat approach was used, with all available
data used for all analyses. One-way analyses of variance were
computed to verify the effects of the adapted randomization pro-
cedure and to ensure that age, stroke severity, and initial arm
function were equivalent across the groups. We hypothesized
that subjects randomized to 14 days of standard intensity or
high-intensity CIM therapy would have greater improvement in
motor function from baseline to 90 days after stroke than sub-
jects randomized to traditional therapy and that they would be
more independent in activities of daily living at 90 days after
stroke. The total ARAT on the more affected side was the pri-
mary dependent measure. Group comparisons were performed
with Proc Mixed, a generalization of the standard linear model
(GLM) procedure to determine if there were significant main
effects for groups and time and a group x time interaction. Ran-
dom coefficient regression is used to examine the response func-
tions of each treatment group over time. Repeated measures
analysis of variance models were fit for each dependent measure
with group assignment (control, standard CIMT, and high-
intensity CIMT) as the between-subject factor and time of as-
sessment (baseline, day 14, and day 90) as the within-subject
factor. Least-square means adjusted for randomly missing values
were computed by group for each time of testing. Type 3 tests of
fixed effects were used for hypothesis testing. If the group x time
interactions were significant (p  0.05) preplanned comparisons
were computed to examine pairwise differences among the three
treatment groups. A futility analysis was conducted after 3 years
of active subject recruitment. The analysis, completed by the
project statistician, confirmed the study was adequately powered
with 52 subjects to test the hypothesis.
RESULTS Figure 1 shows the CONSORT diagram
of participant recruitment. Fifty-two individuals
were randomized and table 1 presents their baseline
characteristics. There were no significant differences
on these variables across the treatment groups. There
were no significant differences between groups in
medical comorbidities: 10% had prior stroke, 65%
had hypertension, 23% had diabetes, 6% had atrial
fibrillation, and 10% had a history of myocardial in-
farction. None was on renal dialysis. Rehabilitation
length of stay was 22.3  7.1 days.
All but two participants were available for assess-
ment at the 90-day primary endpoint. ARAT total
and subtest scores for the affected arm are presented
in table 2. The primary test of the study hypothesis is
the comparison across groups of the slopes of the
total ARAT scores from baseline to day 90 (group x
time). The overall main effect for treatment groups
was not significant (group: F  0.50, p  0.61). As
expected, total ARAT scores improved from baseline
to 90 days for all groups (time: F  45.15, p 
0.0001). There were no significant differences be-
tween the standard CIMT and control patients from
baseline to day 14 or baseline to day 90 (table 2,
figure 2). Unexpectedly, for high-intensity CIMT, a
significant group x time interaction (F  3.06, p 
0.01) was observed for the total ARAT when all three
groups were compared. Contrary to the study hy-
pothesis, high-intensity CIMT patients had signifi-
cantly lower gains in total ARAT scores from
baseline to day 90 than control patients (p  0.006)
or standard CIMT patients (p  0.01). Group com-
parisons of baseline vs day 14 were similar; high-
intensity CIMT patients performed less well than
control patients (p  0.03) or standard CIMT pa-
tients (p  0.003) (see figure 2A).
The same analyses were computed for the ARAT
subtests (table 2). All subtest scores increased signifi-
cantly from baseline to day 90. A group x time inter-
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action was observed for the ARAT pinch subtest
(p  0.03). Pinch scores were highest in the standard
CIMT group at day 14 and day 90 and lowest for the
high-intensity CIMT pinch scores at day 90. The
group x time interactions for the ARAT grip and
gross motor subtests approached but did not reach
statistical significance (p  0.06). High-intensity
CIMT patients had the lowest scores on these
subtests at day 14 and day 90.
We evaluated the effects of standard or high-
intensity CIMT on activities of daily living with the
FIM Upper Extremity Score and the SIS hand sub-
scale (figures 2B and 2C). We found no significant
differences across the three treatment groups for the
FIM Upper Extremity Scale; all groups achieved sim-
ilar gains in function (p  0.16). Mean ratings for
SIS Hand subscale varied by group over the two times
of testing [F(1,50)  3.88, p  0.02]. The control
group scores were higher at day 14, while the standard
CIMT group reported the highest scores at day 90. The
high-intensity CIMT group had significantly lower
scores at day 90 (p  0.02). Thus, CIMT was no more
effective than the control treatment in ameliorating
UE-related disability and the high-intensity CIMT
group had significantly less improvement.
Mean pain scores were low (3 out of 10 possible
points), and shoulder pain increased significantly
from baseline to the 90-day endpoint [F(2,49) 
4.01, p  0.01]. There were no significant differences
among the three treatment groups [F(2,49)  0.22,
p  0.80], and all were similar to the prevalence of
shoulder pain in other cohorts.24 Group means for
the Geriatric Depression Scale were within the nor-
mal range for all three groups at all three time points.
The nine subjects in the MRI substudy were ini-
tially studied 1–22 (mean 13.2) days after onset and
again 7–9 (mean 7.3) days later. Infarct volumes de-
fined by thresholding the DWI/ADC ratio image
ranged from 0.1–13.5 mL. Eight of the nine subjects
(one control, four standard CIMT, and three high-
intensity CIMT) showed no areas of DWI or ADC
change upon visual inspection and had no voxels
with changes in DWI or ADC signal intensities
above threshold. Another control subject had five
scattered voxels above threshold which could be at-
tributed to imaging noise.
DISCUSSION During acute inpatient stroke reha-
bilitation, CIMT was not superior to an equal
amount of traditional occupational therapy. Further,
we found an inverted dose response effect, in which a
higher dose of shaping and constraint led to signifi-
cantly less UE motor improvement at 90 days. These
striking results were consistent across all endpoints.
These results are consistent with other reports,
particularly with studies in which control groups re-
ceived equal amounts of therapy time. CIMT was
found to be superior to an equal amount of neurode-
velopmental treatment in a more clinically heteroge-
neous sample of chronic patients who were at least 1
year poststroke.25 However, this superiority was lim-
ited to the subgroups with sensory loss and hemine-
glect, two groups excluded from VECTORS. A
smaller acute study with a similar design using treat-
ment sessions distributed over 3 weeks, and includ-
ing subjects 2 weeks poststroke, found no difference
in prespecified primary outcomes compared to a
dose-matched control.26 Our prior work found a
benefit for CIMT compared to a dose-matched con-
trol, but the sample was much smaller and the ran-
domized groups were not balanced on important
clinical features.9 A phase III trial of CIMT per-
formed in the 3- to 9-month period poststroke dem-
onstrated the ability of a CIMT program to improve
UE motor function during that period after stroke
when compared to the usual and customary care pro-
vided in the United States.5 Because usual and cus-
tomary care in the United States during this 3- to
9-month period involves far less motor training than
that delivered to the CIMT group, the extent to
which the benefit was related to the CIMT treatment
paradigm, to a nonspecific effect of a higher dose of
motor training, or to both27 is unclear. Two other
studies using a dose-matched control did find CIMT
to be superior, but used a small sample28 or a later
time after stroke onset.29









Age, y 63.9  14 64.7  14.6 62.8  12.8 64.5  15.5
Days since stroke 9.7  4.6 10.4  5.7 8.8  3.1 9.94  4.8
Total NIHSS 5.3  1.8 5.5  1.8 5.1  1.8 5.31  1.8
Total ARAT, impaired 22.5  15.3 19.7  13.9 22.7  14.3 25.4  18.0
FIM motor 57.8  11.1 56.7  12.2 57.1  9.5 59.8  12.1
% Female 60 65 68 44
Race, %
Caucasian 42 47 37 44
African American 57 53 58 56
Affected side, % R 52 52.9 47.4 56.3
% Dominant side affected 44.2 41.2 31.6 62.5
% Prior stroke 10 12 11 6
Stroke lesion
% Ischemic 77 76 74 81
*No significant differences were found between groups for any demographic or clinical
variable.
CIMT  constraint-induced movement therapy; NIHSS  NIH Stroke Scale; ARAT  Action
Research Arm Test; FIM  Functional Independence Measure.
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Our finding of an inverted dose-response curve
bears further comment, and we have considered sev-
eral explanations. In rodent stroke recovery models,
immediate casting of the unaffected forelimb has
been reported to cause lesion enlargement30 that is
presumed excitotoxic31 and is associated with a decre-
ment in motor recovery.32 We found no evidence for
CIMT-caused lesion enlargement in a small MRI
substudy. Shoulder pain and depression have both
been reported to hinder stroke recovery.33 However,
self-reported pain and depression were not signifi-
cantly different across the three study groups. An-
other possible explanation is fatigue or injury related
to overtraining. Overtraining effects are best de-
scribed in the resistance training literature, where ef-
fects of resistance loading and training volume have
been studied in some detail.34 The possibility of over-
training was recently described in another stroke re-
habilitation study using different training modalities
to improve gait35; in this case, however, progressive
lower extremity strength training was an explicit in-
tervention goal, an approach quite unlike CIMT. Yet
another possibility is that increasing the time spent
daily in shaping sessions by 50% effectively led to a
change in practice schedule, from a “distributed”
practice schedule to a more “blocked” schedule.
There is a substantial motor learning literature sug-
gesting that distributed practice schedules lead to
better task learning and performance.36,37 Thus the
extra time spent by the high-intensity CIMT group
actually may have interfered with motor learning.
NIHSS scores were relatively low in our sample, a
consequence of enrolling cognitively capable persons
who had some residual UE motor abilities. Eliminat-
ing persons with complete paralysis or severe disor-
ders of consciousness, sensation, aphasia, or neglect
Figure 2 (A–F) Mixed model analyses of ARAT
total (A), FIM UE scores (B), and SIS
hand function subscale (C)
Group means  SD from the mixed model analyses on the
ARAT total. ARAT  Action Research Arm Test; FIM 
Functional Independence Measure; SIS  Stroke Impact
Scale; CIMT  constraint-induced movement therapy.
Table 2 Least-square mean and standard errors of study outcomes
Control Low CIMT High CIMT F (df  6,49) p
Total ARAT*
Day 0 19.65  3.73 22.68  3.52 25.43  3.84 3.06 0.01
Day 14 36.20  4.05 42.10  3.82 33.93  4.16
Day 90 45.34  3.68 46.86  3.51 38.00  3.76
ARAT grip*
Day 0 4.58  0.88 5.00  0.83 5.19  0.90 2.16 0.06
Day 14 8.32  0.87 9.31  0.81 7.43  0.89
Day 90 9.79  0.78 10.61  0.74 8.37  0.79
ARAT pinch*
Day 0 2.94  1.26 4.73  1.19 6.37  1.30 2.61 0.03
Day 14 7.62  1.68 10.58  1.58 8.75  1.72
Day 90 12.96  1.45 14.39  1.39 10.00  1.48
ARAT grasp*
Day 0 7.11  1.34 7.31  1.27 8.56  1.38 1.52 0.19
Day 14 13.53  1.40 14.21  1.32 11.56  1.43
Day 90 14.33  1.29 15.06  1.23 12.94  1.32
ARAT gross motor*
Day 0 4.88  0.62 5.53  0.58 5.31  0.64 2.15 0.06
Day 14 7.00  0.54 7.79  0.50 6.19  0.55
Day 90 8.08  0.52 8.26  0.50 6.81  0.53
FIM upper extremity
Day 0 22.88  1.22 22.73  1.15 23.69  1.26 1.61 0.16
Day 14 30.23  1.17 30.21  1.11 26.93  1.21
Day 90 32.58  1.15 31.41  1.10 29.12  1.16
Stroke Impact Scale,
hand and arm
Day 0 NA NA NA
Day 14 59.71  6.21 45.26  5.87 44.33  6.61 3.88 0.02
Day 90 72.16  6.37 78.65  6.15 55.00  6.63
*More affected arm.
CIMT  constraint-induced movement therapy; ARAT  Action Research Arm Test; FIM 
Functional Independence Measure.
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must result in NIHSS scores within the range of our
study participants. Because all subjects otherwise re-
ceived usual and customary care after the 14-day
study treatment, data about treatments after dis-
charge were not collected; CIMT was prohibited
outside the study treatment period. Although this
study used a relatively small sample, futility analysis
indicated sufficient power to test the hypothesis.
Our results have two important implications.
First, our finding that equal time of CIMT and con-
ventional therapy were equally effective in ameliorat-
ing UE impairment and disability emphasizes the
need for clinical trials with control groups that match
therapy doses. Without such a control, the superior-
ity of a specific training paradigm cannot be demon-
strated. Second, we found significant dose effects for
training, suggesting that motor training interven-
tions, like drug interventions, can have dose-response
effects. However, as with drugs, it appears possible
that doses higher than an optimal range may be less
effective than lower doses, and even detrimental. Es-
tablishing optimal therapy dosing may require deter-
mination of specific dose-response curves through
clinical studies that directly test different doses of
therapy. Given the large variety of results of timing
and dose studies in rodent models of stroke recovery,
we suggest that such studies must address specific
time points after stroke onset.
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